ARTICLE | Clinical News
NCX 950: Phase I/II
July 15, 2002 7:00 AM UTC
In a double-blind, placebo-controlled, cross-over Swiss Phase I/II study in 24 volunteers, single doses of NCX 950 were safe and well tolerated. NCX 950 was equipotent compared to inhaled salbutamol ...